- Data Covid-19 USA — The approval of Aduhelm to treat Alzheimer’s disease has raised hope among older adults, but many doctors wonder if it is warranted.
- Data Covid-19 USA — The agency’s acting head said a review should look into whether any interactions between agency staff and the drug developer, Biogen, broke F.D.A. rules.
The agency faced criticism for approving Aduhelm for all Alzheimer’s patients. The new label recommends that the drug be given only to patients with mild symptoms.
With the pandemic easing, the federal agency’s long-term agenda for drug approvals or new issues is languishing without a permanent commissioner.
The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.
- Season 2 in Call of Duty — Alles, was ihr zum großen… Das Season 2 Update in Call of Duty ist live! Alle Infos zu Release-Uhrzeit, Patch Notes, Änderungen, Download und Belohnungen.